霍亂疫苗市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、產品、配銷通路、地區和競爭細分，2020-2030 年

2024 年全球霍亂疫苗市場價值為 9,732 萬美元，預計到 2030 年將達到 1.665 億美元，預測期內複合年成長率為 9.32%。全球霍亂疫苗市場受到多種因素的推動，包括霍亂爆發的頻率不斷上升，尤其是在衛生條件不佳和清潔水資源有限的地區。氣候變遷和洪水等自然災害以及持續的衝突進一步加劇了疾病的傳播。更有效的疫苗的開發，具有更高的功效、更持久的保護以及單劑量方案等便捷的給藥方法，刺激了市場需求。各國政府和國際組織對疫苗接種計畫的資助有助於加速全球對抗霍亂的努力。全球旅行導致的人員流動增加也增加了疾病傳播的風險，進一步推動了接種霍亂疫苗以預防疫情的必要性。

主要市場促進因素

霍亂疫情爆發頻率上升

主要市場挑戰

物流和供應鏈障礙

主要市場趨勢

全球旅行和流動性增加

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球霍亂疫苗市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型分類（全細胞霍亂弧菌 O1 與 B 亞單位重組以及去活化口服 O1 和 O139 病毒）
  • 依產品（Vaxchora、Dukoral、Shanchol 等）
  • 按配銷通路（醫院藥房、零售藥房和其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美霍亂疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲霍亂疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太霍亂疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲霍亂疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲霍亂疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Valneva SE
• Sanofi SA
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

第 15 章：策略建議

第16章 關於出版商,免責事項

Global Cholera Vaccines Market was valued at USD 97.32 Million in 2024 and is expected to reach USD 166.50 Million by 2030 with a CAGR of 9.32% during the forecast period. The global cholera vaccine market is driven by several factors, including the rising frequency of cholera outbreaks, especially in regions with poor sanitation and limited access to clean water. Climate change and natural disasters, such as floods, as well as ongoing conflicts, further contribute to the spread of the disease. The development of more effective vaccines, with improved efficacy, longer-lasting protection, and convenient administration methods like single-dose regimens, has boosted market demand. The support of governments and international organizations funding vaccination programs helps accelerate efforts to combat cholera globally. The increased movement of people due to global travel also raises the risk of disease transmission, further driving the need for cholera vaccination to prevent outbreaks.

Key Market Drivers

Rising Frequency of Cholera Outbreaks

The increasing frequency of cholera outbreaks, particularly in regions with poor sanitation and inadequate healthcare infrastructure, is one of the primary factors driving the global cholera vaccine market. Cholera, a highly contagious waterborne disease caused by the Vibrio cholerae bacterium, spreads rapidly in environments where access to clean water is limited, and waste disposal practices are inadequate. Countries with low-income economies, especially those in Sub-Saharan Africa, parts of South Asia, and the Middle East, are seeing frequent cholera outbreaks that put populations at high risk. The World Health Organization (WHO) has released global cholera statistics for 2023, revealing an alarming rise in both cases and deaths. Reported cholera cases increased by 13%, while deaths surged by 71% compared to 2022. Over 4,000 people lost their lives to a disease that is preventable and easily treatable. A total of 45 countries reported cases in 2023, up from 44 the previous year and 35 in 2021. Notably, 38% of the reported cases were among children under five years of age. Cholera, an acute intestinal infection, spreads through contaminated food and water, with communities lacking proper sanitation being the most affected.

Key Market Challenges

Logistical and Supply Chain Barriers

One of the significant challenges to cholera vaccination campaigns is the logistical complexity of vaccine distribution. Many cholera-endemic regions are remote, with limited access to transportation infrastructure, making it difficult to distribute vaccines efficiently. Vaccines often require specific storage conditions, such as refrigeration, which may not be feasible in low-resource settings with inadequate cold chain infrastructure. Political instability, conflicts, and natural disasters can disrupt supply chains and delay vaccination efforts. In regions where cholera outbreaks occur in areas with poor infrastructure, vaccines may not reach the target populations in time to prevent widespread infection. The logistical challenges associated with transporting and storing vaccines in such conditions can limit the effectiveness of vaccination campaigns and prevent the full potential of cholera vaccination from being realized.

Key Market Trends

Increased Global Travel and Mobility

As global travel continues to increase, the risk of infectious diseases, including cholera, spreading across borders has grown. International travel and migration expose individuals to areas with active cholera outbreaks, raising the risk of the disease being transmitted across regions and even continents. Countries with high volumes of international travelers, such as those in Europe, the United States, and the Middle East, are increasingly emphasizing the importance of cholera vaccination to protect travelers and prevent the global spread of the disease. Governments and health authorities have recognized the need for pre-travel vaccinations, particularly for those visiting endemic regions, as a measure to reduce the likelihood of outbreaks in non-endemic areas. In August 2024, Bharat Biotech announced the launch of its new oral cholera vaccine, Hillchol, following successful results from phase 3 trials. Developed under a license from Singapore's Hilleman Laboratories, Bharat Biotech will produce the vaccine with an annual capacity of 200 million doses.

Key Market Players

• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

Report Scope:

In this report, the Global Cholera Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cholera Vaccines Market, By Type:

• Whole cell V. Cholerae O1 Recombinant With B-Subunit
• Killed Oral O1 & O139

Cholera Vaccines Market, By Product:

• Vaxchora
• Dukoral
• Shanchol
• Others

Cholera Vaccines Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Cholera Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholera Vaccines Market.

Available Customizations:

Global Cholera Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholera Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Whole cell V. Cholerae O1 Recombinant With B-Subunit and Killed Oral O1 & O139)
  • 5.2.2. By Product (Vaxchora, Dukoral, Shanchol, and Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Cholera Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cholera Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Cholera Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Cholera Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Distribution Channel

7. Europe Cholera Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cholera Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Cholera Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Cholera Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Cholera Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Cholera Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Cholera Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cholera Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Cholera Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Cholera Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Cholera Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Cholera Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Distribution Channel

9. South America Cholera Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cholera Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Cholera Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Cholera Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Cholera Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cholera Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Cholera Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Cholera Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Valneva SE
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi S.A.
• 14.3. Emergent BioSolutions Inc.
• 14.4. EuBiologics Co., Ltd.
• 14.5. Shantha Biotechnics Limited
• 14.6. Hilleman Laboratories Singapore Pte Ltd
• 14.7. Astellas Pharma Inc.
• 14.8. Incepta Pharmaceuticals Ltd.
• 14.9. Bharat Biotech Ltd.
• 14.10. Takeda Pharmaceutical Company Limited

15. Strategic Recommendations

16. About Us & Disclaimer